Full Press Release Details
Stem Cells as Medicine: The Promise of
Universal Donor Adult Stem Cells Continues to Attract Optimism
Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides
the following discussion on a recent US News and World Report article1
addressing advances of adult stem cells and its own patented stem cell technologies.
Stem cells are broadly categorized into "embryonic"
and "adult" stem cells. Embryonic stem cells are derived from fertilized eggs and hold potential to generate every
major tissue in the body. Unfortunately, embryonic stem cells are difficult to control due to their very immature state. This limits
their ability to be used in patients, which has accounted for a lack of commercial success. In contrast, adult stem cells, which
are classified as every type of stem cell that is not embryonic, are the basis of the technology of the two publicly traded
biotech companies referenced in the article, Mesoblast and Athersys. Currently, Mesoblast is developing stem cells based on bone
marrow stem cells from donors, primarily for treating heart failure, which is in the most advanced phases of clinical trials, termed
Phase III. Additionally, Athersys is also using bone marrow derived stem cells from donors, primarily for use in stroke, which
is also in Phase III clinical trials.
"We at Creative Medical Technologies are encouraged by
this promising article that highlights the important advances being made by adult stem cell companies in addressing the
significant unmet medical needs in degenerative conditions such as stroke and heart failure." Said Timothy Warbington, President
and CEO of Creative Medical Technology Holdings.
"For the past 7 years, we have been working on developing
two types of adult stem cell therapies which are protected by issued US patents."
Our first type of technology is based on a more immediate commercialization,
these therapies use the patient's own unexpanded and minimally manipulated stem cells, termed autologous stem cells, that
can be rapidly implemented because of the long safety record of this type of procedure.
Our CaverstemTM procedure, involves using the patient's
own bone marrow derived stem cells to treat drug-resistant erectile dysfunction. This clinically tried procedure is already being
performed by doctors on the West Coast.
Our second autologous bone marrow stem cell procedure for the
treatment of degenerative disc disease, termed StemSpineTM is in the process of commercialization.
Our second type of technology is a "universal donor"
stem cell that is similar to stem cells developed by Athersys and Mesoblast. In contrast to other universal donor stem cell types,
the stem cell developed by Creative Medical Technology Holdings, Inc., termed "AmnioStemTM is derived from amniotic
fluid, which possesses a higher ability to regenerate tissues as compared to other stem cell types. Our AmnioStemTM,
universal donor stem cell is being developed as a treatment for stroke, with an FDA Investigational New Drug Application (IND)
filing planned to initiate clinical trials.
"I am very impressed with the speed, agility, and precision
that the team at Creative Medical Technology Holdings has displayed in advancing both autologous and allogeneic stem cell therapies."
Said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Director of the Neuroscience Research Center at the Pacific Neuroscience Institute
and Member of Creative Medical Technology Holdings, Inc. Scientific Advisory Board. "I look forward to working with the Company
in advancing its adult stem cell therapy products, which aim to address numerous unmet medical needs."
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial
stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
Chief Executive Officer